Related Experiment Video
Updated: May 17, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Reappraising the use of β-lactams to treat tuberculosis
Sebastian G Kurz1, Robert A Bonomo
1Division of Pulmonary, Critical Care and Sleep Medicine, University Hospitals Case Medical Center and Louis Stokes Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Abstract:
The emergence of multidrug-resistant and extensively drug-resistant tuberculosis calls for novel approaches to treatment. Recent studies have shown that BlaC, the β-lactamase of Mycobacterium tuberculosis, is the major determinant of β-lactam resistance. This review invites the reader to explore evidence in order to answer the questions: can β-lactam and β-lactamase inhibitors adequately treat M. tuberculosis infection and are they a viable option in the management of resistant tuberculosis today?
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Gram-positive Cell Wall Synthesis
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
